Lecanemab Hits PIII Mark with 27% Cut in Clinical Decline, Eisai Set for Submissions by March-End

Eisai CEO Naruo Naito Eisai said on September 28 that its Alzheimer’s drug lecanemab achieved the primary endpoint in a closely watched global PIII study, setting the stage for the company to file for its full approval in Japan, the...read more